Videos

Dr Sanjay Juneja, medical oncologist and hematologist, and Chief of Oncology at Baton Rouge General Hospital–Mary Bird Perkins Cancer Center in Baton Rouge, LA, also known as “The Onc Doc,” is a well-known healthcare influencer. In the video above, Dr Juneja provides his perspectives on key efficacy and safety data from the EMERALD trial, the importance of testing for ESR1 mutations, and what the approval of ORSERDU (elacestrant) means for patients. Read More ›

Welcome to this virtual clinical utility study. It's being done to assess use of a novel biomarker in the treatment decision-making for immunotherapy-eligible first-line advanced stage non-small cell lung cancer patients. Read More ›

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses pivotal presentations from ASCO 2023 focused on metastatic colorectal cancer (mCRC). Read More ›

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses the trends and outcomes of older patients compared to younger patients who received 1L chemotherapy for mCRC. Read More ›

Dr. Sardesai, medical oncologist at The Ohio State University in Columbus, OH, discusses key considerations relating to the approval of ORSERDU (elacestrant), including appropriate patient selection, the clinical relevance of ESR1 mutations, and key takeaways from the EMERALD trial. Read More ›

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he describes the outcomes and study design of clinical trials evaluating targeted therapeutic options for patients with mCRC. Read More ›

Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, explores potential best practice approaches to biomarker testing in mCRC. Read More ›

Dr. Nangia, medical oncologist at Hoag Medical Group in Irvine, CA, discusses key efficacy and safety data from the EMERALD trial, the importance of liquid biopsy testing, and changes in practice brought upon by the approval of ORSERDU (elacestrant). Read More ›

Dr Yuan, medical oncologist in Southern California, discusses key data from the EMERALD trial, the clinical relevance of ESR1 mutations, and changes in practice brought on by the approval of ORSERDU (elacestrant). Read More ›

Dr Tycel Phillips discusses the rationale of an “active surveillance” paradigm following initial diagnosis of follicular lymphoma (FL), as well as how to best select patients in whom this approach could be optimally applied, especially considering FL is currently still an incurable disease. Read More ›